摘要
目的 通过对支气管动脉灌注(BAI)治疗肺癌及经支气管动脉、肺动脉双介入治疗肺癌的生存期随访,探讨支气管动脉灌注及双介入治疗肺癌的临床价值。方法 68例肺癌病人随机分为2组,34例行支气管动脉灌注化疗;34例行支气管动脉、肺动脉双介入治疗,对全部病人生存期随访。结果 单纯支气管动脉灌注化疗病人1、2、3年生存率分别为74%、52%、35.5%;双介入病人1、2、3年生存率分别为72.5%、54%、33%。两组平均生存期分别为25.4个月、23.8个月,无显著性差异(P>0.05)。结论 单纯支气管动脉灌注化疗与支气管动脉、肺动脉双介入治疗肺癌病人生存期无明显差异,且增加手术难度、延长手术时间、使局部用药部分分流、增加术中及术后可能发生的并发症。
Objective To study the clinical value in curing lung cancer with both bronchial artery and pulmonary artery intervene by in- vestigating the survives who were treated with bronchial artery intervene (BAI) or double intervene. Methods 68 Ceases of lung cancer patients randomly divided into two groups and treated with different methods: 34 cases were with BAI, 34 cases were with double intervene in bronchial artery and pulmonary artery. Then investigated them in their exist persiods. Results The survival rate of Purely BAI treated patients were 74%, 52 % and 35.5% . respectively, the other group's were 72.5%, 54% and 33% respectively. The average survival of two groups were 25.4 months and 23.8 months, there is no significant difference between them ( P > 0.05). Conclusions There is no significant difference in exist period between BAI and double intervene treating lung cancer patients. Furthermore it enhances the difficulty of operation and prolongs the time of operation, shunts medicine partly, and adds the chance of complication during and after the operation.
出处
《实用肿瘤学杂志》
CAS
2003年第3期220-222,共3页
Practical Oncology Journal